Ventus Therapeutics
Manufacturing · Canada · 51-200 Employees
View Company Info for Free
Overview
Headquarters
7150 Frederick-banting Ste 200, Montreal...Phone Number
(514) 397-9517Website
www.ventustx.comRevenue
$17.9 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
1
1
1
About Ventus Therapeutics
Ventus Therapeutics specializes in structural immunology to develop therapeutics that target innate immune pathways for various human diseases. Their pipeline includes innovative programs such as VENT-03, a cGAS inhibitor for lupus, and VENT-02, a brain-penetrant NLRP3 inhibitor for Parkinson's disease, both currently in Phase 2 trials. The company aims to address previously undruggable targets and improve treatment options for patients with conditions like IBD and severe asthma. Powered by their ReSOLVE platform, they leverage advances in AI/ML, protein science, and structural biology to enhance drug discovery efficiency.Explore more
Ventus Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Ventus Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Ventus Therapeutics had a recent Job posting/layoffs
Check if Ventus Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Ventus Therapeutics
Ventus Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Ventus Therapeutics is spiking on competitors!
Earning: See what the market has to say on Ventus Therapeutics recently announced quarterly report
Funding: Get notified immidiatlly once Ventus Therapeutics has new funding data
Product Launch: Get notified when Ventus Therapeutics launches new products
Website visits: Recent activity has been detected on your website
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Ventus Therapeutics
Compare insights from companies similar to Ventus Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Ventus Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Ventus Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Ventus Therapeutics.
Ventus Therapeutics financials insights
Gather financial insights about Ventus Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Series A
$60M
2021
Series B
$100M
2022
Series C
$140M
Ventus Therapeutics Tech Stack
A closer look at the technologies used by Ventus Therapeutics
Most Recent Scoops
Open Position
Event
Product Marketing, Events, Learning & Development, Software, Bioengineering, Pharmaceuticals, Public Health, Field /Outside Sales, Field Marketing, Healthcare Technology, Patient Experience
Person-Based
New Hire
Executive Move
Executive Moves, New Hire
Project
Product Development, Research & Development, Medical Research, Pharmaceuticals, Clinical Operations
Ventus Therapeutics News & Media
Ventus Therapeutics to Present at 2025 Bloom Burton & Co. Healthcare Investor Conference
WALTHAM, Mass. & MONTREAL--(BUSINESS WIRE)--Ventus Therapeutics, a leading Phase 2 clinical-stage biopharmaceutical company advancing two novel small-molecule programs for immunological, inflammatory, and neurological disorders, today announced that its President and Chief Executive Officer, Marcelo Bigal, M.D., Ph.D., will present at the 2025 Bloom Burton & Co. Healthcare Investor Conference, being held May 5-6 in Toronto. Dr. Bigal will be presenting on Tuesday, May 6, at 1:30 p.m. ET. AbVentus Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating VENT-02, an Oral, Brain-Penetrant NLRP3 Inhibitor, in Parkinson’s Disease
WALTHAM, Mass. & MONTREAL--(BUSINESS WIRE)--Ventus Therapeutics, a clinical-stage biopharmaceutical company with two novel small-molecule programs entering Phase 2 development for immunological, inflammatory, and neurological disorders, today announced that the first patient has been dosed in a Phase 2a trial of VENT-02 in patients with mild to moderate Parkinson’s disease. VENT-02 is a novel, oral, brain-penetrant inhibitor of NLRP3, a key driver of inflammation and component of the innate immVentus Therapeutics Announces Nature Reviews Immunology Publication Demonstrating the Promise of Caspase-4/5 as Therapeutic Targets
WALTHAM, Mass. & MONTREAL--(BUSINESS WIRE)--Ventus Therapeutics, a clinical-stage biopharmaceutical company with two novel small-molecule programs entering Phase 2 development for immunological, inflammatory, and neurological disorders, today announced a publication in the peer-reviewed journal Nature Reviews Immunology entitled “New insights into the noncanonical inflammasome point to caspase-4 as a druggable target.” The article can be accessed here (doi: 10.1038/s41577-025-01142-9). DespiteVentus Therapeutics Appoints Mona Kotecha, M.D., as Chief Medical Officer
WALTHAM, Mass. & MONTREAL--(BUSINESS WIRE)--Ventus Therapeutics, a clinical-stage biopharmaceutical company with two novel small-molecule programs entering Phase 2 development for immunology, inflammation, and neurology disorders, today announced the appointment of Mona Kotecha, M.D., as Chief Medical Officer. Dr. Kotecha has an extensive track record in drug development and corporate leadership, bringing 20 years of experience in the pharmaceutical industry and patient care. “Mona brings an in
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Top companies in United Kingdom by revenue
Frequently Asked Questions Regarding Ventus Therapeutics
Sign Up For FreeTo access detailed company insights
Ventus Therapeutics specializes in structural immunology to develop therapeutics that target innate immune pathways for various human diseases. Their pipeline includes innovative programs such as VENT-03, a cGAS inhibitor for lupus, and VENT-02, a brain-penetrant NLRP3 inhibitor for Parkinson's disease, both currently in Phase 2 trials. The company... Read More
